NMDA Receptors: Distribution, Role, and Insights into Neuropsychiatric Disorders.

NMDA channel blockers NMDA receptors neuropsychiatric disorders

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 21 08 2024
revised: 12 09 2024
accepted: 16 09 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

N-methyl-D-aspartate receptors (NMDARs) are members of the ionotropic glutamate receptor family. These ligand-gated channels are entwined with numerous fundamental neurological functions within the central nervous system (CNS), and numerous neuropsychiatric disorders may arise from their malfunction. The purpose of the present review is to provide a detailed description of NMDARs by addressing their molecular structures, activation mechanisms, and physiological roles in the mammalian brain. In the second part, their role in various neuropsychiatric disorders including stroke, epilepsy, anti-NMDA encephalitis, Alzheimer's and Huntington's diseases, schizophrenia, depression, neuropathic pain, opioid-induced tolerance, and hyperalgesia will be covered. Finally, through a careful exploration of the main non-competitive NMDARs antagonists (channel-blockers). We discuss the strengths and limitations of the various molecular structures developed for diagnostic or therapeutic purposes.

Sections du résumé

BACKGROUND BACKGROUND
N-methyl-D-aspartate receptors (NMDARs) are members of the ionotropic glutamate receptor family. These ligand-gated channels are entwined with numerous fundamental neurological functions within the central nervous system (CNS), and numerous neuropsychiatric disorders may arise from their malfunction.
METHODS METHODS
The purpose of the present review is to provide a detailed description of NMDARs by addressing their molecular structures, activation mechanisms, and physiological roles in the mammalian brain. In the second part, their role in various neuropsychiatric disorders including stroke, epilepsy, anti-NMDA encephalitis, Alzheimer's and Huntington's diseases, schizophrenia, depression, neuropathic pain, opioid-induced tolerance, and hyperalgesia will be covered.
RESULTS RESULTS
Finally, through a careful exploration of the main non-competitive NMDARs antagonists (channel-blockers).
CONCLUSION CONCLUSIONS
We discuss the strengths and limitations of the various molecular structures developed for diagnostic or therapeutic purposes.

Identifiants

pubmed: 39458906
pii: ph17101265
doi: 10.3390/ph17101265
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Marie Beaurain (M)

ToNIC, Toulouse NeuroImaging Center, INSERM, UPS, Université de Toulouse, 31024 Toulouse, France.

Anne-Sophie Salabert (AS)

ToNIC, Toulouse NeuroImaging Center, INSERM, UPS, Université de Toulouse, 31024 Toulouse, France.

Pierre Payoux (P)

ToNIC, Toulouse NeuroImaging Center, INSERM, UPS, Université de Toulouse, 31024 Toulouse, France.

Emmanuel Gras (E)

Laboratoire Hétérochimie Fondamentale et Appliquée (LHFA, UMR 5069), CNRS, UPS, Université de Toulouse, 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France.

Franck Talmont (F)

Institut de Pharmacologie et de Biologie Structurale (IPBS), CNRS, UPS, Université de Toulouse, 31077 Toulouse, France.

Classifications MeSH